使用不同滤过标志物估算 GFR 的老年人慢性肾脏病患病率和发病率:社区动脉粥样硬化风险研究

IF 3.2 Q1 UROLOGY & NEPHROLOGY Kidney Medicine Pub Date : 2024-08-14 DOI:10.1016/j.xkme.2024.100893
Carina M. Flaherty , Aditya Surapaneni , Jesse C. Seegmiller , Josef Coresh , Morgan E. Grams , Shoshana H. Ballew
{"title":"使用不同滤过标志物估算 GFR 的老年人慢性肾脏病患病率和发病率:社区动脉粥样硬化风险研究","authors":"Carina M. Flaherty ,&nbsp;Aditya Surapaneni ,&nbsp;Jesse C. Seegmiller ,&nbsp;Josef Coresh ,&nbsp;Morgan E. Grams ,&nbsp;Shoshana H. Ballew","doi":"10.1016/j.xkme.2024.100893","DOIUrl":null,"url":null,"abstract":"<div><h3>Rationale &amp; Objective</h3><p>The prevalence of chronic kidney disease (CKD) is known to increase with age; however, creatinine may be a less reliable filtration marker in older adults. Few studies have investigated the prevalence and progression of CKD using different filtration markers for estimating glomerular filtration rate (GFR).</p></div><div><h3>Study Design</h3><p>A prospective observational cohort study.</p></div><div><h3>Setting &amp; Participants</h3><p>6,393 White and African American participants aged 65-100 years from the Atherosclerosis Risk in Communities Study (ARIC) at Visit 5, followed longitudinally at Visits 6 and 7.</p></div><div><h3>Exposure and Outcome</h3><p>The eGFR was estimated either by creatinine (eGFRcr), cystatin C (eGFRcys), creatinine and cystatin C (eGFRcr-cys), or using creatinine, cystatin C, and β-2-microglobulin (eGFRcr-cys-b2m). CKD progression was defined as 30% decline in eGFR at follow-up visits.</p></div><div><h3>Analytical Approach</h3><p>Logistic regression models, adjusted for sex, race and study center, diabetes, blood pressure, body mass index, prevalent cardiovascular disease, and heart failure.</p></div><div><h3>Results</h3><p>At Visit 5, the mean age in the study population was 75.8 years, and the mean eGFR ranged from 71.2 to 61.2<!--> <!-->mL/min/1.73m<sup>2</sup> using eGFRcr or eGFRcys, respectively. The proportion with eGFR<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> was lowest with eGFRcr and highest with eGFRcys for all age groups, and prevalence increased with age for all markers. For example, the prevalence of eGFRcr<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> in ages 70-74 years ranged from 15% to 21% and in ages 85-89 years ranged from 38% to 46% at the different visits. The proportion with a 30% eGFR decline over a mean of 8 years in people who were originally aged 65-69 years ranged from 9% (eGFRcr)-18% (eGFRcys). More people with eGFRcr<!--> <!-->≥<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> were reclassified to<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> when using eGFRcys (33%) compared with eGFRcr-cys (12%) or eGFRcr-cys-b2m (18%). The proportion with 30% eGFR decline was lowest with eGFRcr and highest with eGFRcys, with greater incidence in older age groups for all markers.</p></div><div><h3>Limitations</h3><p>No direct measurement of GFR. Not all participants survived or attended subsequent follow-up visits.</p></div><div><h3>Conclusions</h3><p>The prevalence and progression of CKD increase with age, but estimates vary with the filtration marker used. The eGFRcr gave the lowest estimate of CKD at 15% for people aged 65-69 years at Visit 5 while eGFRcys gave the highest estimates of CKD at 26% for that same population.</p></div><div><h3>Plain Language Summary</h3><p>The study examines different filtration markers for glomerular filtration rate (GFR) equations in older adults. Filtration markers can be affected by age-varying characteristics like muscle mass, so it is important to investigate potential discrepancies in eGFR with different markers. We evaluated eGFR using creatinine, cystatin C, both, and alongside β-2-microglobulin to determine kidney disease prevalence and progression. The main takeaway from this study is that there is variation in prevalence of kidney disease in older adults depending on what filtration marker is used in estimating GFR. Our study falls in line with international kidney guidelines to measure cystatin C more in clinical care, as we may be missing some older adults with kidney disease.</p></div>","PeriodicalId":17885,"journal":{"name":"Kidney Medicine","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590059524001043/pdfft?md5=a377c6f30283bec15957b30a7df1f840&pid=1-s2.0-S2590059524001043-main.pdf","citationCount":"0","resultStr":"{\"title\":\"CKD Prevalence and Incidence in Older Adults Using Estimated GFR With Different Filtration Markers: The Atherosclerosis Risk in Communities Study\",\"authors\":\"Carina M. Flaherty ,&nbsp;Aditya Surapaneni ,&nbsp;Jesse C. Seegmiller ,&nbsp;Josef Coresh ,&nbsp;Morgan E. Grams ,&nbsp;Shoshana H. Ballew\",\"doi\":\"10.1016/j.xkme.2024.100893\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Rationale &amp; Objective</h3><p>The prevalence of chronic kidney disease (CKD) is known to increase with age; however, creatinine may be a less reliable filtration marker in older adults. Few studies have investigated the prevalence and progression of CKD using different filtration markers for estimating glomerular filtration rate (GFR).</p></div><div><h3>Study Design</h3><p>A prospective observational cohort study.</p></div><div><h3>Setting &amp; Participants</h3><p>6,393 White and African American participants aged 65-100 years from the Atherosclerosis Risk in Communities Study (ARIC) at Visit 5, followed longitudinally at Visits 6 and 7.</p></div><div><h3>Exposure and Outcome</h3><p>The eGFR was estimated either by creatinine (eGFRcr), cystatin C (eGFRcys), creatinine and cystatin C (eGFRcr-cys), or using creatinine, cystatin C, and β-2-microglobulin (eGFRcr-cys-b2m). CKD progression was defined as 30% decline in eGFR at follow-up visits.</p></div><div><h3>Analytical Approach</h3><p>Logistic regression models, adjusted for sex, race and study center, diabetes, blood pressure, body mass index, prevalent cardiovascular disease, and heart failure.</p></div><div><h3>Results</h3><p>At Visit 5, the mean age in the study population was 75.8 years, and the mean eGFR ranged from 71.2 to 61.2<!--> <!-->mL/min/1.73m<sup>2</sup> using eGFRcr or eGFRcys, respectively. The proportion with eGFR<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> was lowest with eGFRcr and highest with eGFRcys for all age groups, and prevalence increased with age for all markers. For example, the prevalence of eGFRcr<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> in ages 70-74 years ranged from 15% to 21% and in ages 85-89 years ranged from 38% to 46% at the different visits. The proportion with a 30% eGFR decline over a mean of 8 years in people who were originally aged 65-69 years ranged from 9% (eGFRcr)-18% (eGFRcys). More people with eGFRcr<!--> <!-->≥<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> were reclassified to<!--> <!-->&lt;<!--> <!-->60<!--> <!-->mL/min/1.73m<sup>2</sup> when using eGFRcys (33%) compared with eGFRcr-cys (12%) or eGFRcr-cys-b2m (18%). The proportion with 30% eGFR decline was lowest with eGFRcr and highest with eGFRcys, with greater incidence in older age groups for all markers.</p></div><div><h3>Limitations</h3><p>No direct measurement of GFR. Not all participants survived or attended subsequent follow-up visits.</p></div><div><h3>Conclusions</h3><p>The prevalence and progression of CKD increase with age, but estimates vary with the filtration marker used. The eGFRcr gave the lowest estimate of CKD at 15% for people aged 65-69 years at Visit 5 while eGFRcys gave the highest estimates of CKD at 26% for that same population.</p></div><div><h3>Plain Language Summary</h3><p>The study examines different filtration markers for glomerular filtration rate (GFR) equations in older adults. Filtration markers can be affected by age-varying characteristics like muscle mass, so it is important to investigate potential discrepancies in eGFR with different markers. We evaluated eGFR using creatinine, cystatin C, both, and alongside β-2-microglobulin to determine kidney disease prevalence and progression. The main takeaway from this study is that there is variation in prevalence of kidney disease in older adults depending on what filtration marker is used in estimating GFR. Our study falls in line with international kidney guidelines to measure cystatin C more in clinical care, as we may be missing some older adults with kidney disease.</p></div>\",\"PeriodicalId\":17885,\"journal\":{\"name\":\"Kidney Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-08-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590059524001043/pdfft?md5=a377c6f30283bec15957b30a7df1f840&pid=1-s2.0-S2590059524001043-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kidney Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590059524001043\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590059524001043","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

理论依据和研究目标众所周知,慢性肾脏病(CKD)的患病率会随着年龄的增长而增加;然而,肌酐可能是老年人不太可靠的滤过标志物。很少有研究采用不同的滤过标志物来估算肾小球滤过率(GFR),从而对 CKD 的患病率和进展情况进行调查。暴露和结果eGFR通过肌酐(eGFRcr)、胱抑素C(eGFRcys)、肌酐和胱抑素C(eGFRcr-cys)或肌酐、胱抑素C和β-2-微球蛋白(eGFRcr-cys-b2m)进行估算。分析方法逻辑回归模型,根据性别、种族和研究中心、糖尿病、血压、体重指数、流行性心血管疾病和心力衰竭等因素进行调整。结果在第 5 次随访时,研究人群的平均年龄为 75.8 岁,使用 eGFRcr 或 eGFRcys 的平均 eGFR 分别为 71.2 至 61.2 mL/min/1.73m2 不等。在所有年龄组中,eGFRcr 的 eGFR < 60 mL/min/1.73m2 比例最低,eGFRcys 的 eGFR < 60 mL/min/1.73m2 比例最高,所有指标的患病率都随年龄增长而增加。例如,在不同的访问中,70-74 岁年龄组的 eGFRcr < 60 mL/min/1.73m2 患病率为 15%-21%,85-89 岁年龄组的患病率为 38%-46%。在平均 8 年的时间里,最初年龄为 65-69 岁的人群中 eGFR 下降 30% 的比例从 9% (eGFRcr)到 18% (eGFRcys)不等。与 eGFRcr-cys(12%)或 eGFRcr-cys-b2m(18%)相比,使用 eGFRcys 时,更多 eGFRcr≥60 mL/min/1.73m2 的人被重新分类为 < 60 mL/min/1.73m2(33%)。使用 eGFRcr 时,eGFR 下降 30% 的比例最低,而使用 eGFRcys 时则最高。结论随着年龄的增长,慢性肾功能衰竭的发病率和进展率也会增加,但不同的滤过率指标得出的估计值也不同。eGFRcr 对第 5 次随访时 65-69 岁人群的 CKD 估计值最低,为 15%,而 eGFRcys 对同一人群的 CKD 估计值最高,为 26%。滤过标志物会受到肌肉质量等年龄变化特征的影响,因此研究不同标志物对 eGFR 的潜在差异非常重要。我们使用肌酐、胱抑素 C 和β-2-微球蛋白评估了 eGFR,以确定肾脏疾病的患病率和进展情况。这项研究的主要启示是,老年人肾脏疾病的患病率存在差异,这取决于在估算肾小球滤过率时所使用的滤过标志物。我们的研究符合国际肾脏指南的要求,即在临床护理中更多地测量胱抑素 C,因为我们可能遗漏了一些患有肾脏疾病的老年人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CKD Prevalence and Incidence in Older Adults Using Estimated GFR With Different Filtration Markers: The Atherosclerosis Risk in Communities Study

Rationale & Objective

The prevalence of chronic kidney disease (CKD) is known to increase with age; however, creatinine may be a less reliable filtration marker in older adults. Few studies have investigated the prevalence and progression of CKD using different filtration markers for estimating glomerular filtration rate (GFR).

Study Design

A prospective observational cohort study.

Setting & Participants

6,393 White and African American participants aged 65-100 years from the Atherosclerosis Risk in Communities Study (ARIC) at Visit 5, followed longitudinally at Visits 6 and 7.

Exposure and Outcome

The eGFR was estimated either by creatinine (eGFRcr), cystatin C (eGFRcys), creatinine and cystatin C (eGFRcr-cys), or using creatinine, cystatin C, and β-2-microglobulin (eGFRcr-cys-b2m). CKD progression was defined as 30% decline in eGFR at follow-up visits.

Analytical Approach

Logistic regression models, adjusted for sex, race and study center, diabetes, blood pressure, body mass index, prevalent cardiovascular disease, and heart failure.

Results

At Visit 5, the mean age in the study population was 75.8 years, and the mean eGFR ranged from 71.2 to 61.2 mL/min/1.73m2 using eGFRcr or eGFRcys, respectively. The proportion with eGFR < 60 mL/min/1.73m2 was lowest with eGFRcr and highest with eGFRcys for all age groups, and prevalence increased with age for all markers. For example, the prevalence of eGFRcr < 60 mL/min/1.73m2 in ages 70-74 years ranged from 15% to 21% and in ages 85-89 years ranged from 38% to 46% at the different visits. The proportion with a 30% eGFR decline over a mean of 8 years in people who were originally aged 65-69 years ranged from 9% (eGFRcr)-18% (eGFRcys). More people with eGFRcr  60 mL/min/1.73m2 were reclassified to < 60 mL/min/1.73m2 when using eGFRcys (33%) compared with eGFRcr-cys (12%) or eGFRcr-cys-b2m (18%). The proportion with 30% eGFR decline was lowest with eGFRcr and highest with eGFRcys, with greater incidence in older age groups for all markers.

Limitations

No direct measurement of GFR. Not all participants survived or attended subsequent follow-up visits.

Conclusions

The prevalence and progression of CKD increase with age, but estimates vary with the filtration marker used. The eGFRcr gave the lowest estimate of CKD at 15% for people aged 65-69 years at Visit 5 while eGFRcys gave the highest estimates of CKD at 26% for that same population.

Plain Language Summary

The study examines different filtration markers for glomerular filtration rate (GFR) equations in older adults. Filtration markers can be affected by age-varying characteristics like muscle mass, so it is important to investigate potential discrepancies in eGFR with different markers. We evaluated eGFR using creatinine, cystatin C, both, and alongside β-2-microglobulin to determine kidney disease prevalence and progression. The main takeaway from this study is that there is variation in prevalence of kidney disease in older adults depending on what filtration marker is used in estimating GFR. Our study falls in line with international kidney guidelines to measure cystatin C more in clinical care, as we may be missing some older adults with kidney disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Kidney Medicine
Kidney Medicine Medicine-Internal Medicine
CiteScore
4.80
自引率
5.10%
发文量
176
审稿时长
12 weeks
期刊最新文献
Living Donor Candidates’ Self-reported Health and Health Perceptions and Completion of Donor Evaluation: A Cohort Study Undetected Air Embolism During Hemodialysis from a Defective Central Venous Catheter Causing Intradialytic Cardiac Arrest: An Imaging Teaching Case The Surprise Question in Hemodialysis, Frailty, Nutrition, Patient-reported Quality of Life, and All-Cause Mortality: The Osaka Dialysis Complication Study (ODCS) Antihypertensive Treatment Patterns in CKD Stages 3 and 4: The CKD-REIN Cohort Study Advanced CKD of Uncertain Etiology Among Children in Guatemala: Genetic and Clinical Characteristics
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1